Cogent Biosciences (COGT) Enterprise Value (2020 - 2026)
Cogent Biosciences' Enterprise Value history spans 10 years, with the latest figure at -$866.4 million for Q1 2026.
- Quarterly Enterprise Value fell 252.67% to -$866.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$866.4 million through Mar 2026, down 252.67% year-over-year, with the annual reading at -$900.8 million for FY2025, 213.77% down from the prior year.
- Enterprise Value came in at -$866.4 million for Q1 2026, up from -$900.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$141.8 million in Q3 2022 to a low of -$900.8 million in Q4 2025.
- The 5-year median for Enterprise Value is -$287.1 million (2024), against an average of -$354.0 million.
- Year-over-year, Enterprise Value skyrocketed 43.62% in 2025 and then crashed 252.67% in 2026.
- Cogent Biosciences' Enterprise Value stood at -$259.3 million in 2022, then dropped by 2.48% to -$265.7 million in 2023, then dropped by 8.04% to -$287.1 million in 2024, then crashed by 213.77% to -$900.8 million in 2025, then grew by 3.82% to -$866.4 million in 2026.
- Per Business Quant, the three most recent readings for COGT's Enterprise Value are -$866.4 million (Q1 2026), -$900.8 million (Q4 2025), and -$390.9 million (Q3 2025).